Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Endo International PLC (NASDAQ:ENDP)

7.57
Delayed Data
As of 4:00pm ET
 +0.30 / +4.13%
Today’s Change
5.77
Today|||52-Week Range
17.99
-54.04%
Year-to-Date
Endo (ENDP) Earnings & Revenues Beat in Q3, Generics Weak
Nov 10 / Zacks.com - Paid Partner Content
Implied Volatility Surging for Endo (ENDP) Stock Options
Nov 09 / Zacks.com - Paid Partner Content
BioDelivery (BDSI) Q3 Earnings, Sales Beat Estimates
Nov 10 / Zacks.com - Paid Partner Content
 

Today’s Trading

Previous close7.27
Today’s open7.30
Day’s range7.30 - 7.60
Volume4,352,318
Average volume (3 months)6,660,134
Market cap$1.6B
Dividend yield--
Data as of 4:00pm ET, 11/21/2017

Growth & Valuation

Earnings growth (last year)-96.37%
Earnings growth (this year)-22.56%
Earnings growth (next 5 years)-13.10%
Revenue growth (last year)+22.69%
P/E ratioNM
Price/Sales0.91
Price/Book0.60

Competitors

 Today’s
change
Today’s
% change
CORTCorcept Therapeutics...+0.49+2.87%
AERIAerie Pharmaceutical...+1.70+2.85%
AXONAxovant Sciences Ltd+0.08+1.49%
TBPHTheravance Biopharma...-0.04-0.14%
Data as of 4:00pm ET, 11/21/2017

Financials

Next reporting dateFebruary 28, 2018
EPS forecast (this quarter)$0.64
Annual revenue (last year)$4.0B
Annual profit (last year)-$3.3B
Net profit margin-80.39%

Profile

Sector
Health Technology
Industry
Pharmaceuticals: Other
President, Chief Executive Officer &
Director
Paul V. Campanelli
Chief Operating Officer &
Executive Vice President
Terrance J. Coughlin
Corporate headquarters
Dublin, Dublin

Forecasts